5 Key Takeaways
-
1
The Via360 surgical system combines canaloplasty and trabeculotomy, offering enhanced control over viscoelastic delivery during glaucoma surgery.
-
2
The system received FDA 510(k) clearance in February 2025 for controlled viscoelastic delivery and trabecular meshwork incisions.
-
3
ActiveInject technology allows surgeons to deliver viscoelastic on demand, independent of catheter movement, enhancing procedural efficiency.
-
4
The device's microcatheter can advance 360° within Schlemm's canal, facilitating targeted treatment of outflow resistance.
-
5
Clinical experience indicates the Via360 system effectively reduces intraocular pressure and medication burden in patients with various glaucoma types.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.